Ironwood Pharmaceuticals (NASDAQ:IRWD) : Traders are bullish on Ironwood Pharmaceuticals (NASDAQ:IRWD) as it has outperformed the S&P 500 by a wide margin of 2.24% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 0.08%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 1.36% in the last 1 week, and is up 3.89% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have rallied 17.08% from its 1 Year high price. On Jul 8, 2016, the shares registered one year high at $13.43 and the one year low was seen on Feb 8, 2016. The 50-Day Moving Average price is $12.72 and the 200 Day Moving Average price is recorded at $10.91.
The stock has recorded a 20-day Moving Average of 4.2% and the 50-Day Moving Average is 11.63%.
Ironwood Pharmaceuticals (NASDAQ:IRWD): stock turned positive on Friday. Though the stock opened at $13.11, the bulls momentum made the stock top out at $13.43 level for the day. The stock recorded a low of $12.9 and closed the trading day at $13.37, in the green by 1.91%. The total traded volume for the day was 1,166,994. The stock had closed at $13.12 in the previous days trading.
In an insider trading activity, The Securities and Exchange Commission has divulged that Olanoff Lawrence S, director of Ironwood Pharmaceuticals Inc, had unloaded 2,200 shares at an average price of $12.92 in a transaction dated on June 3, 2016. The total value of the transaction was worth $28,424.
Ironwood Pharmaceuticals, Inc. is a pharmaceutical company. The Company has a product, linaclotide, which is available in the United States and Mexico under the brand name LINZESS, and is available in European countries and Canada under the brand name CONSTELLA. Linaclotide is also being developed and commercialized in other parts of the world by certain of its partners. Linaclotide provides patients and healthcare practitioners with a treatment option for adults in the United States and certain other countries with irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC) and gastrointestinal (GI) disorders. The Company in collaboration with Astellas Pharma Inc. (Astellas) is developing linaclotide for the treatment of patients with IBS-C.